Identification of cholesterol 25-hydroxylase as a novel host restriction factor and a part of the primary innate immune responses against hepatitis C virus infection

Journal of Virology

Volumn 89, Issue 13, 2015, Pages 6805-6816

  Xiang, Yu ^a   Tang, Jing Jie ^b   Tao, Wanyin ^a   Cao, Xuezhi ^a   Song, Bao Liang ^c   Zhong, Jin ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL 25 HYDROXYLASE; INTERFERON; LIPID; OXYGENASE; POLYINOSINIC POLYCYTIDYLIC ACID; STAT1 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; 25-HYDROXYCHOLESTEROL; CHOLESTEROL 25-HYDROXYLASE; CHOLESTEROL DERIVATIVE; IMMUNOLOGIC FACTOR; STEROID MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTERFERON STIMULATED GENE; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; CELL LINE; DRUG EFFECTS; GENE SILENCING; HEPACIVIRUS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

FLAVIVIRIDAE; HEPATITIS C VIRUS; MUS; RNA VIRUSES;

CELL LINE; GENE KNOCKDOWN TECHNIQUES; HEPACIVIRUS; HEPATOCYTES; HUMANS; HYDROXYCHOLESTEROLS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; STEROID HYDROXYLASES; VIRUS REPLICATION;

EID: 84930908151     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00587-15     Document Type: Article

References (52)

1. Liang TJ, Ghany MG. 2013. Current and future therapies for hepatitis C virus infection. N Engl J Med 368:1907-1917. http://dx.doi.org/10.1056/NEJMra1213651.
2. Agnello V, Ábel G, Elfahal M, Knight GB, Zhang Q-X. 1999. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad SciUSA 96:12766-12771. http://dx.doi.org/10.1073/pnas.96.22.12766.
3. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017-5025. http://dx.doi.org/10.1093/emboj/cdf529.
4. Hsu N-Y, Ilnytska O, Belov G, Santiana M, Chen Y-H, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJM, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles forRNAreplication. Cell 141:799-811. http://dx.doi.org/10.1016/j.cell.2010.03.050.
5. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089-1097. http://dx.doi.org/10.1038/ncb1631.
6. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 104:5848-5853. http://dx.doi.org/10.1073/pnas.0700760104.
7. Waris G, Felmlee DJ, Negro F, Siddiqui A. 2007. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 81:8122-8130. http://dx.doi.org/10.1128/JVI.00125-07.
8. Oem J-K, Jackel-Cram C, Li Y-P, Zhou Y, Zhong J, Shimano H, Babiuk LA, Liu Q. 2008. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus nonstructural protein 2. J Gen Virol 89:1225-1230. http://dx.doi.org/10.1099/vir.0.83491-0.
9. Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ. 2013. Hepatitis C virus infection activates an innate pathway involving IKK- in lipogenesis and viral assembly. Nat Med 19:722-729. http://dx.doi.org/10.1038/nm.3190.
10. Ramalho F. 2003. Hepatitis C virus infection and liver steatosis. Antivir Res 60:125-127. http://dx.doi.org/10.1016/j.antiviral.2003.08.007.
11. Goldstein JL, DeBose-Boyd RA, Brown MS. 2006. Protein sensors for membrane sterols. Cell 124:35-46. http://dx.doi.org/10.1016/j.cell.2005.12.022.
12. Pai J-t, Guryev O, Brown MS, Goldstein JL. 1998. Differential stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells expressing individual nuclear sterol regulatory element-binding proteins. J Biol Chem 273:26138-26148. http://dx.doi.org/10.1074/jbc.273.40.26138.
13. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. 2007. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi:oxysterols block transport by binding to Insig. Proc Natl Acad SciUSA 104:6511-6518. http://dx.doi.org/10.1073/pnas.0700899104.
14. Gong Y, Lee JN, Lee PCW, Goldstein JL, Brown MS, Ye J. 2006. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab 3:15-24. http://dx.doi.org/10.1016/j.cmet.2005.11.014.
15. Lund EG. 1998. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 273:34316-34327. http://dx.doi.org/10.1074/jbc.273.51.34316.
16. Cyster JG, Dang EV, Reboldi A, Yi T. 2014. 25-Hydroxycholesterols in innate and adaptive immunity. Nat Rev Immunol 14:731-743. http://dx .doi.org/10.1038/nri3755.
17. Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 2009. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci U S A 106:16764-16769. http://dx.doi.org/10.1073/pnas.0909142106.
18. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, Flaring U, Bjorkbacka H. 2009. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J Lipid Res 50:2258-2264. http://dx.doi.org/10.1194/jlr.M900107-JLR200.
19. Park K, Scott AL. 2010. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol 88:1081-1087. http://dx.doi.org/10.1189/jlb.0610318.
20. Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, Lacaze P, Watterson S, Griffiths SJ, Spann NJ, Meljon A, Talbot S, Krishnan K, Covey DF, Wenk MR, Craigon M, Ruzsics Z, Haas J, Angulo A, Griffiths WJ, Glass CK, Wang Y, Ghazal P. 2013. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity 38:106-118. http://dx.doi.org/10.1016/j.immuni.2012.11.004.
21. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, Freiberg AN, Su L, Lee B, Cheng G. 2013. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 38:92-105. http://dx.doi.org/10.1016/j.immuni.2012.11.005.
22. Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N, Shu HB, Zhong J. 2013. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J Hepatol 59:52-58. http://dx.doi.org/10.1016/j.jhep.2013.03.019.
23. Chen W, Xu Y, Li H, Tao W, Xiang Y, Huang B, Niu J, Zhong J, Meng G. 2014. HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells. PLoS One 9:e84953. http://dx.doi.org/10.1371/journal .pone.0084953.
24. Tao W, Xu C, Ding Q, Li R, Xiang Y, Chung J, Zhong J. 2009. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. Virology 395:67-76. http://dx.doi .org/10.1016/j.virol.2009.09.006.
25. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
26. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14:25-27. http://dx.doi.org/10.1038/nm1698.
27. Ding Q, Huang B, Lu J, Liu Y-J, Zhong J. 2012. Hepatitis C virus NS3/4A protease blocks IL-28 production. Eur J Immunol 42:2374-2382. http://dx.doi.org/10.1002/eji.201242388.
28. Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, Song BL. 2011. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab 13:44-56. http://dx.doi.org/10.1016/j.cmet.2010.12.004.
29. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84-87. http://dx.doi.org/10.1126/science.1247005.
30. Cao X, Ding Q, Lu J, Tao W, Huang B, Zhao Y, Niu J, Liu YJ, Zhong J. 2014. MDA5 plays a critical role in interferon response during hepatitis C virus infection. J Hepatol 62:771-778. http://dx.doi.org/10.1016/j.jhep .2014.11.007.
31. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99:15669-15674. http://dx.doi.org/10.1073/pnas.202608199.
32. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
33. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich H-G, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796. http://dx .doi.org/10.1038/nm1268.
34. Lu J, Xiang Y, Tao W, Li Q, Wang N, Gao Y, Xiang X, Xie Q, Zhong J. 2014. Anovel strategy to develop a robust infectious hepatitisCvirus cell culture system directly from a clinical isolate. J Virol 88:1484-1491. http://dx.doi.org/10.1128/JVI.02929-13.
35. Bartosch B, Dubuisson J, Cosset F-L. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633-642. http://dx.doi.org/10.1084/jem.20021756.
36. Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, Conrads TP, Wang T. 2008. Fatty acid synthase is upregulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology 48:1396-1403. http://dx.doi.org/10.1002/hep.22508.
37. Ye J, Wang C, Sumpter R, Jr, Brown MS, Goldstein JL, Gale M, Jr. 2003. Disruption of hepatitisCvirusRNAreplication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100:15865-15870. http://dx.doi.org/10.1073/pnas.2237238100.
38. Olmstead AD, Knecht W, Lazarov I, Dixit SB, Jean F. 2012. Human subtilase SKI-1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents. PLoS Pathog 8:e1002468. http://dx.doi.org/10.1371/journal.ppat.1002468.
39. Adams CM, Reitz J, De Brabander JK, Feramisco JD, Li L, Brown MS, Goldstein JL. 2004. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J Biol Chem 279:52772-52780. http://dx.doi.org/10.1074/jbc.M410302200.
40. Jiang W, Tang J-J, Miao H-H, Qu Y-X, Qin J, Xu J, Yang J, Li B-L, Song B-L. 2014. Forward genetic screening for regulators involved in cholesterol synthesis using validation-based insertional mutagenesis. PLoS One 9:e112632. http://dx.doi.org/10.1371/journal.pone.0112632.
41. Naganuma A, Dansako H, Nakamura T, Nozaki A, Kato N. 2004. Promotion of microsatellite instability by hepatitis C virus core protein in human non-neoplastic hepatocyte cells. Cancer Res 64:1307-1314. http://dx.doi.org/10.1158/0008-5472.CAN-03-2992.
42. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454:523-527. http://dx.doi.org/10.1038/nature07106.
43. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. 2005. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 102:17717-17722. http://dx.doi.org/10.1073/pnas.0508531102.
44. Cheng G, Zhong J, Chisari FV. 2006. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and independent mechanisms. Proc Natl Acad SciUSA 103:8499-8504. http://dx.doi.org/10.1073/pnas.0602957103.
45. Zou T, Garifulin O, Berland R, Boyartchuk VL. 2011. Listeria monocytogenes infection induces prosurvival metabolic signaling in macrophages. Infect Immun 79:1526-1535. http://dx.doi.org/10.1128/IAI.01195-10.
46. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G. 2012. Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A 109:4239-4244. http://dx.doi.org/10.1073/pnas.1114981109.
47. Civra A, Cagno V, Donalisio M, Biasi F, Leonarduzzi G, Poli G, Lembo D. 2014. Inhibition of pathogenic nonenveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol. Sci Rep 4:7487. http://dx .doi.org/10.1038/srep07487.
48. Chen Y, Wang S, Yi Z, Tian H, Aliyari R, Li Y, Chen G, Liu P, Zhong J, Chen X, Du P, Su L, Qin FX, Deng H, Cheng G. 2014. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep 4:7242. http://dx.doi.org/10.1038/srep07242.
49. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, Kawai T, Hoshino K, Takeda K, Akira S. 2004. The roles of two IkB kinase-related kinases in lipopolysaccharide and double-stranded RNA signaling and viral infection. J Exp Med 199:1641-1650. http://dx.doi.org/10.1084/jem.20040520.
50. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907.
51. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. 2012. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56:2082-2093. http://dx.doi.org/10.1002/hep.25908.
52. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142:978-988. http://dx.doi.org/10.1053/j .gastro.2011.12.055.